Repression of HIP/RPL29 expression induces differentiation in colon cancer cells

Journal of Cellular Physiology

Volumn 207, Issue 2, 2006, Pages 287-292

  Liu, Jian Jun ^a   Huang, Bao Hua ^a   Zhang, Jinqiu ^a   Carson, Daniel D ^b   Hooi, Shing Chuan ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF DELAWARE   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BUTYRIC ACID; GALECTIN 4; GLUCOSE; HEPARAN SULFATE INTERACTING PROTEIN; MUCIN 2; PROTEIN P21; PROTEIN P53; PROTEIN TCF 4; RIBOSOMAL PROTEIN L29; RIBOSOME PROTEIN; SMALL INTERFERING RNA; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER TISSUE; CELL DIFFERENTIATION; CELL STRAIN HT29; COLON CANCER; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE EPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM;

ALKALINE PHOSPHATASE; BETA CATENIN; BLOOD COAGULATION FACTORS; BUTYRATES; CELL DIFFERENTIATION; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; GALECTIN 4; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; HCT116 CELLS; HT29 CELLS; HUMANS; MUCINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645677937     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20589     Document Type: Article

References (31)

1. Bellamy CO. 1997. p53 and apoptosis. Br Med Bull 53(3):522-538.
2. Chylicki K, Ehinger M, Svedberg H, Gullberg U. 2000. Characterization of the molecular mechanisms for p53-mediated differentiation. Cell Growth Differ 11(11):561-571.
3. de Nigris F, Visconti R, Cerutti J, Califano D, Mineo A, Santoro M, Santelli G, Fusco A. 1998. Overexpression of the HIP gene coding for a heparin/heparan sulfate-binding protein in human thyroid carcinomas. Cancer Res 58(20):4745-4751.
4. Evers BM. 1999. Intestinal cell differentiation: Cellular mechanisms and the search for the perfect model focus on "involvement of p21(WAF1/Cip1) and p27(Kip1) in intestinal epithelial cell differentiation". Am J Physiol 276(6 Pt 1):C1243-C1244.
5. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP. 2002. HDAC6 is a microtubule-associated deacetylase. Nature 417(6887):455-458.
6. Iozzo RV. 1988a. Cell surface heparan sulfate proteoglycan and the neoplastic phenotype. J Cell Biochem 37(1):61-78.
7. Iozzo RV. 1988b. Proteoglycans and neoplasia. Cancer Metastasis Rev 7(1):39-50.
8. Jacobs AL, Julian J, Sahin AA, Carson DD. 1997. Heparin/heparan sulfate interacting protein expression and functions in human breast cancer cells and normal breast epithelia. Cancer Res 57(22):5148-5154.
9. Kolligs FT, Bommer G, Goke B. 2002. Wnt/beta-catenin/tcf signaling: A critical pathway in gastrointestinal tumorigenesis. Digestion 66(3):131-144.
10. Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher PB. 2001. Differentiation therapy of human cancer: Basic science and clinical applications. Pharmacol Ther 90(2-3):105-156.
11. Liu S, Smith SE, Julian J, Rohde LH, Karin NJ, Carson DD. 1996. cDNA cloning and expression of HIP, a novel cell surface heparan sulfate/heparin- binding protein of human uterine epithelial cells and cell lines. J Biol Chem 271(20):11817-11823.
12. Liu S, Hoke D, Julian J, Carson DD. 1997a. Heparin/heparan sulfate (HP/HS) interacting protein (HIP) supports cell attachment and selective, high affinity binding of HP/HS. J Biol Chem 272(41):25856-25862.
13. Liu S, Zhou F, Hook M, Carson DD. 1997b. A heparin-binding synthetic peptide of heparin/heparan sulfate-interacting protein modulates blood coagulation activities. Proc Natl Acad Sci USA 94(5):1739-1744.
14. Liu S, Julian J, Carson DD. 1998. A peptide sequence of heparin/heparan sulfate (HP/HS)-interacting protein supports selective, high affinity binding of HP/HS and cell attachment. J Biol Chem 273(16):9718-9726.
15. Liu JJ, Zhang J, Ramanan S, Julian J, Carson DD, Hooi SC. 2004. Heparin/heparan sulfate interacting protein plays a role in apoptosis induced by anticancer drugs. Carcinogenesis 25(6):873-879.
16. Lynch RG. 1995. Differentiation and cancer: The conditional autonomy of phenotype. Proc Natl Acad Sci USA 92(3):647-648.
17. Miller SA, Brown AJ, Farach-Carson MC, Kirn-Safran CB. 2003. HIP/BPL29 down-regulation accompanies terminal chondrocyte differentiation. Differentiation 71(6):322-336.
18. Porrello A, Cerone MA, Coen S, Gurtner A, Fontemaggi G, Cimino L, Piaggio G, Sacchi A, Soddu S. 2000. p53 regulates myogenesis by triggering the differentiation activity of pRb. J Cell Biol 151(6):1295-1304.
19. Raboudi N, Julian J, Rohde LH, Carson DD. 1992. Identification of cell-surface heparin/heparan sulfate-binding proteins of a human uterine epithelial cell line (RL95). J Biol Chem 267(17):11930-11939.
20. Raff MC. 1992. Social controls on cell survival and cell death. Nature 356(6368):397-400.
21. Rechreche H, Mallo GV, Montalto G, Dagorn JC, Iovanna JL. 1997. Cloning and expression of the mRNA of human galectin-4, an S-type lectin down-regulated in colorectal cancer. Eur J Biochem 248(1):225-230.
22. Rohde LH, Julian J, Babaknia A, Carson DD. 1996. Cell surface expression of HIP, a novel heparin/heparan sulfate binding protein, of human uterine epithelial cells and cell lines. J Biol Chem 271(20):11824-11830.
23. Ruoslahti E, Yamaguchi Y. 1991. Proteoglycans as modulators of growth factor activities. Cell 64(5):867-869.
24. Schwartz B, Lamprecht SA, Polak-Charcon S, Niv Y, Kim YS. 1995. Induction of the differentiated phenotype in human colon cancer cell is associated with the attenuation of subcellular tyrosine phosphorylation. Oncol Res 7(6):277-287.
25. Sionov RV, Haupt Y. 1998. Apoptosis by p53: Mechanisms, regulation, and clinical implications. Springer Semin Immunopathol 19(3):345-362.
26. Ta TV, Baraniak D, Julian J, Korostoff J, Carson DD, Farach-Carson MC. 2002. Heparan sulfate interacting protein (HIP/L29) negatively regulates growth responses to basic fibroblast growth factor in gingival fibroblasts. J Dent Res 81(4):247-252.
27. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals S, Eilers M, Medema R, Clevers H. 2002. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111(2):241-250.
28. Waltzer L, Bienz M. 1999. The control of beta-catenin and TCF during embryonic development and cancer. Cancer Metastasis Rev 18(2):231-246.
29. Wang Y, Cheong D, Chan S, Hooi SC. 1999. Heparin/heparan sulfate interacting protein gene expression is up-regulated in human colorectal carcinoma and correlated with differentiation status and metastasis. Cancer Res 59(12):2989-2994.
30. Wight TN, Kinsella MG, Qwarnstrom EE. 1992. The role of proteoglycans in cell adhesion, migration and proliferation. Curr Opin Cell Biol 4(5):793-801.
31. Zweibaum A, Pinto M, Chevalier G, Dussaulx E, Triadou N, Lacroix B, Haffen K, Brun JL, Rousset M. 1985. Enterocytic differentiation of a subpopulation of the human colon tumor cell line HT-29 selected for growth in sugar-free medium and its inhibition by glucose. J Cell Physiol 122(1):21-29.